NASDAQ : PPBT
Purple Biotech Ltd — Key statistics
Healthcare · Biotechnology · Israel
Last price 1.17 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 10.49M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 10.49M |
| Enterprise Value | 4.68M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 2.17B |
| Shares Change (YoY) | +267.67% |
| Shares Change (QoQ) | +16.70% |
| Owned by Insiders (%) | 0.32% |
| Owned by Institutions (%) | 12.24% |
| Float | 3.23B |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.86 |
| P/TBV Ratio | 2.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.70 |
| Quick Ratio | 3.42 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -876.22 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -111.13% |
| Return on Assets (ROA) | -20.31% |
| Return on Invested Capital (ROIC) | -22.15% |
| Return on Capital Employed (ROCE) | -63.68% |
| Weighted Average Cost of Capital (WACC) | 1.29% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.45M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.55 |
| 52-Week Price Change | -88.96% |
| 50-Day Moving Average | 1.46 |
| 200-Day Moving Average | 3.02 |
| Relative Strength Index (RSI) | 45.25 |
| Average Volume (20 Days) | 23,632 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 16,344 |
| Short Previous Month | 18,115 |
| Short % of Shares Out | 1.00% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.43 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -59,000 |
| Operating Income | -7.89M |
| Pretax Income | -24.60M |
| Net Income | -24.49M |
| EBITDA | -7.84M |
| EBIT | -7.89M |
| Earnings Per Share (EPS) | -$5.02 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6.11M |
| Total Debt | 134,000 |
| Net Cash | 5.97M |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 12.21M |
| Book Value Per Share | 0.01 |
| Working Capital | 4.81M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.76M |
| Capital Expenditures | -4,000 |
| Depreciation & Amortization | 46,000 |
| Net Borrowing | -250,000 |
| Free Cash Flow | -7.76M |
| FCF Per Share | -$0.00 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -267.67% |
| Shareholder Yield | n/a |
| Earnings Yield | -429.08% |
| FCF Yield | -74.03% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |